LRP2 and central nervous system cancer: The results showed that LRP2 mutations were associated with better prognosis in endometrial cancer (OS, p < 0.001), bladder urothelial carcinoma (OS, p = 0.0061) and brain lower grade glioma (OS, p < 0.0293) (Fig. 1H).